These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9131174)
1. Lexipafant (BB-882), a potent PAF antagonist in acute pancreatitis. Curtis LD Adv Exp Med Biol; 1996; 416():361-3. PubMed ID: 9131174 [No Abstract] [Full Text] [Related]
2. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824 [TBL] [Abstract][Full Text] [Related]
3. The use of lexipafant in the treatment of acute pancreatitis. McKay C; Curran FJ; Sharples CE; Young CA; Baxter JN; Imrie CW Adv Exp Med Biol; 1996; 416():365-70. PubMed ID: 9131175 [TBL] [Abstract][Full Text] [Related]
4. Effect of a platelet-activating factor antagonist on pancreatitis-associated gut barrier dysfunction in rats. Andersson R; Wang X; Sun Z; Deng X; Soltesz V; Ihse I Pancreas; 1998 Aug; 17(2):107-19. PubMed ID: 9700940 [TBL] [Abstract][Full Text] [Related]
5. Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant. Leveau P; Wang X; Sun Z; Börjesson A; Andersson E; Andersson R Biochem Pharmacol; 2005 May; 69(9):1325-31. PubMed ID: 15826603 [TBL] [Abstract][Full Text] [Related]
6. Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials. Abu-Zidan FM; Windsor JA Eur J Surg; 2002; 168(4):215-9. PubMed ID: 12440758 [TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Suputtamongkol Y; Intaranongpai S; Smith MD; Angus B; Chaowagul W; Permpikul C; Simpson JA; Leelarasamee A; Curtis L; White NJ Antimicrob Agents Chemother; 2000 Mar; 44(3):693-6. PubMed ID: 10681340 [TBL] [Abstract][Full Text] [Related]
9. Lung injury in the microembolic model of acute pancreatitis and amelioration by lexipafant (BB-882), a platelet-activating factor antagonist. Galloway SW; Kingsnorth AN Pancreas; 1996 Aug; 13(2):140-6. PubMed ID: 8829181 [TBL] [Abstract][Full Text] [Related]
10. Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis. Wang X; Sun Z; Börjesson A; Haraldsen P; Aldman M; Deng X; Leveau P; Andersson R Int J Pancreatol; 1999 Feb; 25(1):45-52. PubMed ID: 10211421 [TBL] [Abstract][Full Text] [Related]
11. Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis. Lane JS; Todd KE; Gloor B; Chandler CF; Kau AW; Ashley SW; Reber HA; McFadden DW J Surg Res; 2001 Aug; 99(2):365-70. PubMed ID: 11469912 [TBL] [Abstract][Full Text] [Related]
12. BB-882 is a potent antagonist of the haemodynamic changes induced by platelet-activating factor in pigs. Abu-Zidan FM; Walther S; Lennquist S Pharmacol Toxicol; 1996 Jan; 78(1):23-7. PubMed ID: 8685082 [TBL] [Abstract][Full Text] [Related]
13. Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis. Meenan J; Grool TA; Hommes DW; Dijkhuizen S; ten Kate FJ; Wood M; Whittaker M; Tytgat GN; van Deventer SJ Eur J Gastroenterol Hepatol; 1996 Jun; 8(6):569-73. PubMed ID: 8823572 [TBL] [Abstract][Full Text] [Related]
14. Therapy for acute pancreatitis with platelet-activating factor receptor antagonists. Chen C; Xia SH; Chen H; Li XH World J Gastroenterol; 2008 Aug; 14(30):4735-8. PubMed ID: 18720532 [TBL] [Abstract][Full Text] [Related]
15. [New aspects of pharmaco-therapy for acute pancreatitis]. Takase K; Ueda T; Kuroda Y Nihon Rinsho; 2004 Nov; 62(11):2074-8. PubMed ID: 15552891 [TBL] [Abstract][Full Text] [Related]
16. The scientific basis of medical therapy of acute pancreatitis. Could it work, and is there a role for lexipafant? Imrie CW; McKay CJ Gastroenterol Clin North Am; 1999 Sep; 28(3):591-9, ix. PubMed ID: 10503138 [TBL] [Abstract][Full Text] [Related]
17. Hope or hype for lexipafant? Abu-Zidan FM Nature; 1998 Oct; 395(6701):431. PubMed ID: 9774090 [No Abstract] [Full Text] [Related]
18. Influence of the platelet-activating factor receptor antagonist BB-882 on intra-abdominal adhesion formation in rats. Otcu S; Ozturk H; Aldemir M; Kilinc N; Dokucu AI Eur Surg Res; 2003; 35(1):41-5. PubMed ID: 12566786 [TBL] [Abstract][Full Text] [Related]
19. Therapy for microcirculatory disorders in severe acute pancreatitis: effectiveness of platelet-activating factor receptor blockade vs. endothelin receptor blockade. Foitzik T; Hotz HG; Eibl G; Hotz B; Kirchengast M; Buhr HJ J Gastrointest Surg; 1999; 3(3):244-51. PubMed ID: 10481117 [TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Kingsnorth AN; Galloway SW; Formela LJ Br J Surg; 1995 Oct; 82(10):1414-20. PubMed ID: 7489182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]